Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hemiasterlin SCHEMBL22692376 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL14567797 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL13850381 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL57334 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL4173 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL29421592 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL14115433 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| Hemiasterlin SCHEMBL13203800 | 1.00 | TUBB1 (0.61) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| SCHEMBL26607783 | 0.94 | TUBB1 (0.53) | TUBB1GLAALDH1A1SMN1; SMN2NR4A2 | |
| SCHEMBL58604 | 0.93 | TUBB1 (0.52) | TUBB1GLAALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029793-B2 | pH low insertion peptide targeted delivery of potent cytotoxic compounds | YALE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029793-B2 | pH low insertion peptide targeted delivery of potent cytotoxic compounds | YALE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023077129-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3892305-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Sutro Biopharma, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
| EP-3250237-B1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7410951-B2 | Biologically active peptides and compositions, their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844090-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | TUBB1 176/4885GLA 1187/4885ALDH1A1 1882/4885 |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | TUBB1 176/4885GLA 1187/4885ALDH1A1 1882/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | TUBB1 1668/4885GLA 1444/4885ALDH1A1 1175/4885 |
| US-12029793-B2 | pH low insertion peptide targeted delivery of potent cytotoxic compounds | SLC7A1, SLC47A1, VIP | TUBB1 3218/4885GLA 3616/4885ALDH1A1 4770/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | TUBB1 1157/4885GLA 456/4885ALDH1A1 3053/4885 |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | TUBB1 176/4885GLA 1187/4885ALDH1A1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.